Ocular immunology and inflammation · 2022
Effect of Anti-TNF Treatment on Mooren's Ulcer: A Case Series and Review of the Literature.
ОбзорСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Annie, Dietrich-Ntoukas Tina, Pleyer Uwe
Аннотация
PURPOSE: To report the efficacy of systemic anti-TNF agents in Mooren's ulcer.
DESIGN: Retrospective, consecutive case series.
METHODS: We report on clinical characteristics and outcome of five patients with Mooren's ulcer with anti-TNF treatment.
RESULTS: During a mean follow-up of 30 months, relief of symptoms and arrest of corneal melting were observed in all eyes. Systemic corticosteroid treatment could be discontinued or reduced to threshold levels. No patient experienced adverse effects on bDMARDs.
CONCLUSIONS: Our results suggest that bDMARDs are effective in Mooren's ulcer unresponsive to conventional treatment. This is in line with accumulating evidence in the current literature. Therefore, more targeted immunomodulatory approaches might be an effective first-line therapy in the future.
DESIGN: Retrospective, consecutive case series.
METHODS: We report on clinical characteristics and outcome of five patients with Mooren's ulcer with anti-TNF treatment.
RESULTS: During a mean follow-up of 30 months, relief of symptoms and arrest of corneal melting were observed in all eyes. Systemic corticosteroid treatment could be discontinued or reduced to threshold levels. No patient experienced adverse effects on bDMARDs.
CONCLUSIONS: Our results suggest that bDMARDs are effective in Mooren's ulcer unresponsive to conventional treatment. This is in line with accumulating evidence in the current literature. Therefore, more targeted immunomodulatory approaches might be an effective first-line therapy in the future.